Celgene (CELG) Given Hold Rating at Cantor Fitzgerald

Celgene (NASDAQ:CELG)‘s stock had its “hold” rating reissued by equities researchers at Cantor Fitzgerald in a research note issued to investors on Monday. They presently have a $112.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 8.46% from the stock’s previous close.

The analysts wrote, “CELG’s current CEO, Mark Alles, will assume the role of Chairman of the Board, following the retirement of current COB Robert Hugin, effective February 5th, which follows his departure as President in early 2016.””

Several other research firms have also weighed in on CELG. Royal Bank of Canada restated a “buy” rating and set a $173.00 price target on shares of Celgene in a research report on Thursday, October 5th. Morgan Stanley lowered shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research report on Thursday, October 5th. Vetr upgraded shares of Celgene from a “hold” rating to a “buy” rating and set a $146.58 price target for the company in a research report on Friday, October 6th. Zacks Investment Research lowered shares of Celgene from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. Finally, Barclays increased their target price on shares of Celgene from $135.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. Celgene has a consensus rating of “Buy” and a consensus price target of $130.35.

Celgene (NASDAQ:CELG) traded down $1.91 on Monday, reaching $103.26. 7,028,937 shares of the company traded hands, compared to its average volume of 8,612,313. The company has a market capitalization of $81,100.00, a price-to-earnings ratio of 28.60, a P/E/G ratio of 0.70 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene has a one year low of $94.55 and a one year high of $147.17.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The company had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 64.14%. The firm’s revenue for the quarter was up 16.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.61 earnings per share. equities analysts predict that Celgene will post 7.82 EPS for the current year.

Several institutional investors have recently made changes to their positions in CELG. Braun Stacey Associates Inc. lifted its holdings in shares of Celgene by 32.1% in the second quarter. Braun Stacey Associates Inc. now owns 54,371 shares of the biopharmaceutical company’s stock worth $7,061,000 after buying an additional 13,201 shares in the last quarter. Busey Trust CO raised its stake in Celgene by 0.7% in the second quarter. Busey Trust CO now owns 61,790 shares of the biopharmaceutical company’s stock valued at $8,025,000 after purchasing an additional 432 shares in the last quarter. ST Germain D J Co. Inc. raised its stake in Celgene by 6.1% in the second quarter. ST Germain D J Co. Inc. now owns 8,977 shares of the biopharmaceutical company’s stock valued at $1,166,000 after purchasing an additional 518 shares in the last quarter. Brave Asset Management Inc. raised its stake in Celgene by 0.4% in the second quarter. Brave Asset Management Inc. now owns 43,252 shares of the biopharmaceutical company’s stock valued at $5,656,000 after purchasing an additional 187 shares in the last quarter. Finally, Essex Investment Management Co. LLC raised its stake in Celgene by 6.7% in the second quarter. Essex Investment Management Co. LLC now owns 119,981 shares of the biopharmaceutical company’s stock valued at $15,582,000 after purchasing an additional 7,537 shares in the last quarter. 79.71% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/29/celgene-celg-given-hold-rating-at-cantor-fitzgerald.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply